Results for tag: "Fibrodysplasia Ossificans Progressiva"

Fibrodysplasia Ossificans Progressiva (FOP) is a rare, genetic disorder of the connective tissue that causes muscle tissue and connective tissue such as tendons and ligaments to be gradually replaced by bone, forming bone outside the skeleton (extra-skeletal or heterotopic bone) that constrains movement. Musculoskeletal Disorders Drugs are used to treat FOP, including bisphosphonates, which are used to reduce the activity of cells that cause the formation of extra-skeletal bone, and corticosteroids, which are used to reduce inflammation. Other treatments include physical therapy, occupational therapy, and surgery. Companies in the FOP market include Novartis, which produces the bisphosphonate Aclasta, and Pfizer, which produces the corticosteroid Xeljanz. Other companies include Sanofi, which produces the bisphosphonate Zometa, and Regeneron, which produces the bisphosphonate Arcalyst. Show Less Read more